InvestSMART

Mayne Pharma Group Limited (ASX:MYX)

ALERT: Price-sensitive ASX Announcement for MYX
Current share price for MYX : $3.120 0.52 (20%)+
Announcement
Release
31 Jul 2026 9:29AM
Price at Release
$2.600
Full Release
download
Summary
Mayne Pharma Group Limited reported its unaudited financial results for the fourth quarter and full fiscal year ending 30 June 2026. The company's revenue for Q4 FY26 was AUD 86.5 million, a 22% decline from the same period in the previous year, primarily due to reduced dermatology sales. However, the Women's Health portfolio, particularly BIJUVA® and NEXTSTELLIS®, showed robust growth with significant increases in total prescriptions. The company's full-year revenue was AUD 383.7 million, marking a 6% decline from FY25. Despite these challenges, including disruptions from the Cosette transaction, Mayne Pharma is focusing on expansion and strategic investments, notably in its Women's Health sales and promotional capabilities, and the new DistributeRx distribution platform. The company is also preparing for the expansion of its Adelaide Apothecary facility and exploring additional global partnerships.
Key Points
  • Women's Health portfolio led by BIJUVA® and NEXTSTELLIS® showed strong prescription growth.
  • Q4 FY26 revenue was AUD 86.5 million, down 22% from the previous year.
  • FY26 revenue totalled AUD 383.7 million, a 6% decrease year-over-year.
  • Mayne Pharma received AUD 14.4 million from Cosette for recovery of legal costs.
  • DistributeRx platform successfully launched, expanding distribution capabilities.
  • Strategic investments in Women's Health to support long-term growth.
  • Challenges faced due to Cosette transaction and foreign exchange impacts.
  • Gross margin improved to 65% in Q4 FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.